Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

NCT01932554 is registered in ClinicalTrials.gov with St. Louis University as lead sponsor.

NCT NCT01932554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01932554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
Lead sponsor
St. Louis University
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2013
Completion date
March 31, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hb-ss disease with vasoocclusive pain, hemoglobin ss disease with crisis, hemoglobin ss disease with vasoocclusive crisis, other sickle cell disease with vaso-occlusive pain, sickle cell disease